Pfizer Begins Human Testing for Experimental Coronavirus Vaccine In the US
Pfizer said Tuesday it has begun testing an experimental vaccine to combat the coronavirus in the United States. The U.S.-based pharmaceutical giant, which is working alongside German drugmaker BioNTech, said the first human participants in the United States have been dosed with the potential vaccine, BNT162, according to a CNBC report. They began human trials of the experimental vaccine late last month in Germany.
“With our unique and robust clinical study program underway, starting in Europe and now the U.S., we look forward to advancing quickly and collaboratively with our partners at BioNTech and regulatory authorities to bring a safe and efficacious vaccine to the patients who need it most,” Pfizer Chairman and CEO Albert Bourla said in a statement.